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Abstract (271 words) 
Antibody-mediated rejection (AMR) is difficult to diagnose after ABO-compatible or 
ABO-identical (ABO-C) liver transplantation. To confirm whether C4d immunostaining is 
useful for diagnosing AMR, we compared the results of C4d immunohistochemistry in 
allograft biopsies with assays for anti-donor antibodies performed at the time of biopsies. 
A total of 114 patients with ABO-C grafts and 29 patients with ABO-incompatible 
(ABO-I) grafts were included. Linear C4d endothelial staining identifiable by x4 objective 
lens or staining seen in >50% of portal tracts was considered positive.  
Five of 114 (4%) patients with ABO-C and 15 of 29 (52%) patients with ABO-I showed 
C4d positivity. In ABO-C cases, C4d positivity was associated with ≥stage 2 fibrosis 
(METAVIR score) and presence of donor-specific anti-HLA DR  antibodies (HLA-DR 
DSA) with more than 5000 mean fluorescence intensity (MFI) by the Luminex single 
antigen bead assay in late (≥30 days posttransplantation) biopsies (p=0.01 and 0.04, 
respectively). Conversely, presence of HLA-DR DSA was associated with presence of 
≥stage 2 fibrosis, acute cellular rejection, and C4d positivity. During two-year follow-up, 
neither C4d positivity nor HLA-DR DSA was related to graft loss. In ABO-I, C4d 
positivity was not associated with allograft dysfunction or fibrosis. Only three of 15 (20%) 
C4d-positive patients showed periportal hemorrhagic edema, which could be a 
histological sign of AMR in ABO-I, and were the only cases associated with elevations in 
anti-donor A/B antibody titers. In conclusion, C4d endothelial positivity in ABO-C was an 
uncommon event that could be associated with chronic graft damage with or without 
clinical AMR. C4d positivity is common in ABO-I grafts, and may not be associated with 
allograft dysfunction if alloantibody titers are not elevated. 
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Antibody-mediated rejection (AMR) in liver allografts is recognized as a possible cause of 
early and late allograft injury, and poor prognosis (1-8). However, unlike acute cellular or 
chronic rejection, the diagnosis of AMR in liver allografts is often difficult to establish. 
One of the main reasons for this is due to the difficulty in interpreting C4d deposition, 
which is the most widely used marker of clinical AMR in renal, cardiac, and pancreatic 
transplantations (8-11).  
The specificity of C4d staining in liver allografts is controversial. Ali S et al. (3) and Lunz 
J et al. (4) correlated diffuse portal tract vascular endothelial C4d deposition with AMR. 
However, C4d positivity was also reported in other medical conditions, such as acute 
cellular rejection (ACR) (1,3-5,12,13), chronic rejection (CR) (3,5,12,13), ischemic injury 
(1,3,12), hepatitis (1,3,4,14) and cholangitis (1,3,4). Unfortunately, most of these previous 
studies performed C4d staining on non-consecutive biopsies from unstable liver grafts 
(15). A more comprehensive study is required to understand the significance of C4d and 
its utility in AMR, in combination with tests for alloantibodies.  
In addition, sites of C4d deposition differ between and within these reports, including 
portal vessels (1-6,12,14), portal stroma (1,2,5), and sinusoids (3,4,5,12). The lack of 
agreement in staining patterns may also be related to the low specificity of C4d for AMR 
and may prevent clinicians and pathologists from using C4d in the routine histological 
diagnosis of liver allografts. 
Kozlowski et al. (7) recently suggested that strong linear staining in the sinusoid, rather 
than the portal tract, was a better marker for AMR and recommended the use of 
immunofluorescence on frozen sections. As they pointed out, immunoperoxidase staining 
is insensitive and frozen sections may be a better tool to demonstrate C4d deposition. 
However, frozen sections are not suitable for conventional histological evaluations, and 
formalin-fixed paraffin embedded tissue is additionally required. Considering the rarity 
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of clinical AMR in liver transplantation (LT), we suggest that establishing a method to 
evaluate C4d by immunoperoxidase alone may be practical. 
Here, we designed a non-selective prospective study in which we performed C4d staining 
on all liver allograft biopsies obtained over four consecutive months, and every clinically 
indicated biopsy was included in this study. The presence of anti-blood group (Anti-A/B) 
antibodies or anti-human leukocyte antigen (anti-HLA) antibodies was evaluated during 
the same period. All patients were followed up for 2 years to clarify the significance of 
C4d in liver allografts. We adopted endothelial staining for this study although we 
previously reported the stromal deposition of C4d as an ominous sign of ABO-I LT (2). 
The main reason to exclude stromal staining in this study was that only endothelial 
staining has been used as the standard in other solid organ transplantations (16). The 
second reason is that stromal staining alone is often difficult to differentiate from the 
non-specific staining seen in elastic fibers or necrotic tissue (1, 17). When we picked up 
every portal stromal or endothelial staining, C4d staining was seen in various types of 
liver allograft injuries and did not show clinical significance (1). Since extensive C4d 
staining covers the endothelia of portal, sinusoidal, and perivenular areas (1, 2), we now 
assume that endothelial staining alone is adequate for evaluating C4d.   
 
Materials and methods 
Study population and biopsies 
In a prospective and non-selective manner, regardless of indication, we studied all liver 
allograft biopsies obtained between July and October 2011 at Kyoto University Hospital. 
Patients who underwent LT outside Kyoto University hospital were not included. Liver 
allograft biopsies were performed to determine allograft dysfunction or evaluate graft 
fibrosis when immunosuppression weaning was intended. If a patient underwent 
multiple biopsies during this period, the first biopsy that showed C4d positivity was 
Salah. C4d immunohistochemistry in liver allografts 6 
selected for analysis. When all biopsies were negative for C4d, the first biopsy was 
selected. In each case, the biopsy specimen for analysis was classified as early (taken 
within 30 days after transplantation) or late (taken 30 days or more after 
transplantation). All patients were followed up until July 2013. Clinical and serological 
data were obtained from electronic patient charts. The Institutional Review Board of 
Kyoto University approved this study. 
 
Immunosuppression 
The baseline immunosuppression protocol consisted of tacrolimus and oral prednisolone 
in both ABO-C and ABO-I patients. The lower limit of the target for whole blood 
tacrolimus levels was 10 to 15 ng/mL during the first 2 weeks, 10 ng/mL thereafter, and 5 
to 8 ng/mL from the second month on. Acute rejection was treated by a 3-day course of 
intravenous methylprednisolone bolus therapy (10 mg/kg). Mycophenolate mophetil was 
administered to patients who underwent refractory rejection or plasma cell hepatitis 
simulating autoimmune hepatitis. Immunosuppression was weaned in selected pediatric 
patients, according to the previously described protocol (18). All ABO-I patients 
underwent preoperative plasmapheresis or blood exchange in order to reduce antidonor 
A/B antibodies to 1:8 or lower. In addition, patients who underwent ABO-I 
transplantation after 2006 received rituximab (anti-CD 20 monoclonal antibody) 
approximately two weeks before transplantation (19). Adult patients were given 
prostaglandin E1 and methylprednisolone via a portal vein or hepatic artery. Clinical 
AMR, consisted of an elevation in postoperative anti-donor A/B antibody titers and graft 
dysfunction, was treated for about 5 days by plasmapheresis or intravenous 
immunoglobulin, with steroid bolus therapy. 
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Histopathology 
Liver allograft biopsies were processed for routine light microscopy. Biopsy specimens 
were fixed in 10% buffered formalin, sliced 3 µm thick, and stained with hematoxylin and 
eosin (H&E), Masson Trichrome, and Cytokeratin 7 (clone OV-TL 12/30, Dako, Glostrup, 
Denmark; dilution 1:200). 
ACR and chronic rejection were diagnosed according to Banff criteria (20, 21).  AMR was 
diagnosed according to the criteria used in other solid organ transplantations; i) clinical 
evidence of graft dysfunction, ii) histologic evidence of graft injury, iii) immunopathologic 
evidence of antibody action (C4d deposition), and iv) serologic evidence of anti-HLA or 
anti-donor antibodies at time of the biopsy (22). A combination of periportal edema, 
hemorrhage, and neutrophilic infiltration was regarded as an indicator of AMR in ABO-I 
patients (8,23). Allograft fibrosis was staged according to the METAVIR scoring system 
(24). 
 
C4d immunohistochemical staining 
A rabbit polyclonal anti-human C4d antibody (BIOMEDIA, Bl-RC4D, 1:50 dilution) was 
used to detect C4d.  Staining was performed on an autostainer machine (Ventana 
Benchmark ULTRA). Sections were treated with protease (Ventana, 0.5 U/mL) at 37 °C 
for 20 minutes for antigen retrieval. C4d immunostaining using formalin-fixed, paraffin 
embedded tissue was available in our laboratory since August 2003, but it was applied 
only to selected cases and was not used routinely before this study. 
 
C4d interpretation 
Staining was recorded as diffuse when linear C4d deposition in the portal tract vascular 
endothelium was seen in 50% or more of portal tracts. Staining of fewer than 50% of 
portal tracts was considered focal. We also evaluated the intensity of staining, which was 
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recorded as strong when linear C4d deposition was seen on low power magnification (x4 
objective lens), and weak when staining was confirmed only on higher magnification. 
Completely negative (Score 0) or focally weak (Score 1) staining was considered negative 
and equivocal, respectively. Diffuse or strong (Score 2) as well as diffuse and strong (Score 
3) staining was considered positive for statistical analysis. Staining in hepatocytes, portal 
stroma, and elastic fibers was recorded but not included for statistical analysis. All 
stained slides were interpreted by M. F. and H. H. without clinical data. 
 
Assays for alloantibodies 
The lymphocyte cross-match test was only conducted before transplantation (25). After 
LT, the anti-HLA antibody titer was analyzed using Luminex multiplex technology at the 
time of the biopsy. The specificity of positive tests was determined using the LABScreen 
Single Antigen test (LABScreen Mixed and LABScreen Single Antigen, One Lambda, 
Canoga Park, CA) and the results were displayed as mean fluorescence intensity (MFI). 
MFI of more than 5000 was regarded as positive (13). The anti-HLA antibody was then 
compared with the patient’s HLA type to decide whether it was a donor-specific antigen 
(DSA) or non-DSA.  
In ABO-I cases, serum levels of anti-A/B antibodies were evaluated before and after LT 
using the microhemagglutination assay. This test was conducted at least 3 times per 
week during the first postoperative month. A postoperative anti-donor blood group 
immunoglobulin M titer of 1:32 or more was defined as an elevated titer. 
 
Statistical analysis  
Associations between categorical variables were assessed using Fisher’s exact test. 
Descriptive statistical methods (mean, median, standard deviation, range) as well as the 
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Mann-Whitney U test were used to assess the distribution of variables. For all analyses, a 
P value of less than 0.05 was regarded as significant. 
 
Results 
Patient Characteristics  
A total of 219 biopsies obtained from 163 patients (range: 1 to 9 per patient) during this 
study period. After excluding 20 ABO-C patients whose Luminex assays for anti-HLA 
antibodies were not available at the time of index biopsy, 143 patients with a total of 194 
biopsies were enrolled in this study. Seven ABO-I patients who underwent isoagglutinin 
tests but not Luminex assays were not eliminated. 
The demographic of patients is summarized in Table 1. Most patients (98%) underwent 
living donor LT. The most common indications for transplantation in pediatric and adult 
groups were biliary atresia and chronic hepatitis C, respectively. In the ABO-C group, 
there were 114 patients and had a higher percentage of children (being less than 18 years 
old, 74% vs. 38%) and most (91%) of their index biopsy were taken more than 30 days 
after transplantation. In the ABO-I group, there were 29 patients, and acute cellular 
rejection, C4d positivity, and graft loss were more commonly seen than the ABO-C group. 
All patients were lymphocyte cross-match negative before transplantation. No significant 
difference was observed in the percentage of positivity for anti-HLA-DSA antibodies 
between the ABO-C group and the ABO-I group. We also checked the data using cut-off 
point of 1000 MFI and there was no difference between the two groups (data not shown). 
The distribution of HLA-DSA by class among patients was as follows: 1 class I, 36 class II, 
and 3 class I and II. Among 39 patients with anti-class II antibodies, antibodies against 
DR loci were most commonly observed (n = 27, 69%). Among 96 HLA-DSA-negative 
patients, 22 showed non-donor-specific HLA antibody (>1000 MFI), 7 weak class II 
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(>1000 and ≤5000 MFI against donor DR locus), 2 weak class I, and 65 patients were 
completely negative for anti-HLA antibody. 
Three ABO-C patient and 6 ABO-I patients died during the follow-up period, and none of 
them showed positivity for the anti-HLA antibody or high anti-A/B antibody titers. For 2 
ABO-I patients, data of Luminex assays were not performed before death. All the ABO-C 
patients were negative for C4d, while five of the six (83%) ABO-I showed C4d positivity. 
Four patients died of severe bacterial or fungal infection within six months after LT. The 
other five died of severe acute cellular rejection (7 months after LT), graft-versus-host 
disease (14 months after LT), fibrosing cholestatic hepatitis C (15 months after LT), 
ischemic cholangiopathy after rupture of the hepatic artery (6 years after LT), and 
cirrhosis due to de novo autoimmune hepatitis (14 years after LT), respectively. 
 
Characteristics of C4d-positive cases in ABO-compatible or identical transplantation 
Table 2 lists the clinical and histological characteristics of 20 patients exhibiting C4d 
positivity at index biopsy. In early biopsies of the ABO-C group, only one of 10 patients  
was positive for C4d (Case C1) and statistical analysis was not suitable for this subgroup 
(Table 3). The previous biopsy of C1 (POD 7) showing moderate degree of acute cellular 
rejection was also C4d-positive but was out of this study period.  
In late biopsies of the ABO-C group, C4d immunoreactivity was significantly correlated 
with graft bridging fibrosis (P = 0.01) but not with histology of acute cellular rejection, 
levels of serum transaminases or total bilirubin (Table 3). Although positivity for 
anti-DSA antibody itself was not statistically associated with C4d positivity, presence of 
DSA against DR loci was correlated with C4d status (P=0.04). Inclusion of anti-HLA-DQ 
antibody status made the difference statistically insignificant (data not shown). When 
late biopsies were divided in terms of donor-specific anti-HLA-DR antibody, Presence of 
donor-specific anti-HLA-DR antibody was significantly associated with fibrosis, acute 
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cellular rejection and C4d score but not with levels of serum transaminase or total 
bilirubin (Table 4).  
C4d-positive cases in late biopsy included heterogeneous histology with various possible 
causes of fibrosis (C2, C3, C4, C5 in Table 2); C2 and C3 were pediatric protocol biopsies 
with minimal or no inflammatory cell infiltration, and C4d positivity was thought be 
related to suboptimal immunosuppression.  
Case C4 was obtained from a patient whose recurrent hepatitis C was treated with 
interferon since７months after LT at stage 1 fibrosis. Although sustained virus response 
was achieved, the biopsy taken five years after LT revealed progression of fibrosis and 
focal ductopenia (Figure 1A and 1B). This patient was found to have low titer of 
anti-nuclear antibody, but histology was different from autoimmune hepatitis and 
compatible with chronic cholangiopathy (Figure 1C). There was a history of biliary 
anastomotic stricture 2 year after LT and the patient underwent a successful removal of 
biliary casts. Diffuse C4d staining was noted in the fibrous portal tracts (Figure 1D), and 
C4d positivity persisted in the biopsy taken a year after this study period. Another 
patient with a history of recurrent hepatitis C, Case C5, was DSA-negative at the time of 
index biopsy with interferon therapy. When follow-up biopsy was done after cessation of 
unsuccessful interferon therapy, C4d became negative (Table 2). 
Although no patient was diagnosed with clinical AMR in the patients with ABO-C LT in 
this study period, one patient was revealed to have persistent graft dysfunction along 
with persistent DSA, and a history of sporadic C4d staining. Before transplantation, the 
lymphocyte cross-match test was negative and the Luminex test was not available. Three 
allograft biopsies within three months posttransplantation showed acute cellular 
rejection and C4d staining was negative each time. In spite of the long-term use of triple 
immunosuppressants (tacrolimus, prednisolone, and mycophenolate mofetil), graft 
dysfunction persisted and histological diagnosis after 6 months was mild acute cellular 
Salah. C4d immunohistochemistry in liver allografts 12 
rejection with perivenular hemorrhage (Figure 2A). Diffuse endothelial C4d staining with 
some stromal staining was seen in biopsies taken at postoperative day (POD) 185, 192, 
and 227 (Figure 2B). The Luminex test revealed DSA at POD 229 (B59, 3932; DR4, 
15840; DR53; 8061; DQ4, 4747). During this study period (POD 524), portal inflammation 
was mild (Figure 2C) and C4d staining was faint and considered negative (Figure 2D). 
DSA remained positive (B59, 3434; DR4, 12318; DR53, 2444) and portal and perivenular 
fibrosis progressed (Figure 2E). Serum bilirubin levels remained at 2 to 3 mg/dL. On the 
last follow-up biopsy taken at POD 986, DSA remained positive (B59, 4509; DR4, 6458; 
DR53, 23557; DQ4, 23738) with persistent fibrosis and ductular reaction. Bile duct loss 
was not observed. C4d endothelial staining returned (Figure 2F).  
 
Characteristics of C4d-positive cases in ABO-incompatible transplantation 
In both early and late biopsies, C4d status in ABO-I LT was not statistically associated 
with any clinical parameters possibly related to rejection (Table 5). The majority of 
C4d-positive patients did not show postoperative elevations in anti-donor A/B antibody 
titers in spite of C4d endothelial staining (I1-15, Table 2). Only 3 patients (I1, I8, and I12) 
showed anti-A/B antibody titer elevations, and they were the only patients that fulfilled 
the criteria for AMR: 1) detectable anti-donor antibody (1:32 or more anti A/B antibody 
with or without the presence of an anti-HLA antibody), 2) C4d in the graft endothelium, 
3) graft pathology, and 4) graft dysfunction. These three patients showed typical 
ABO-I-associated injuries, characterized by portal edema and hemorrhage, with foci of 
necrosis (Figure 3A). Sinusoidal C4d staining was also observed in Case I8 (Figure 3B). 
All ABO-I AMR cases responded well to steroid pulse therapy with or without 
plasmapheresis and immunoglobulin bolus administration. The level of isoagglutinin 
decreased to 1:4 or lower after therapy for AMR. Follow-up biopsies showed diffuse C4d 
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positivity in Case I8, equivocal (score 1) staining in Case I1, and complete negativity in 
Case I12 (Table 5) 59, 390, and 169 days after index biopsies, respectively. 
All C4d staining in ABO-I LT tended to fade in the follow-up biopsies. Only in 3 of 11 last 




This study showed that C4d positivity without an elevation in anti-donor A/B antibodies 
was not uncommon among patients with ABO-I LT. Before the use of rituximab, we 
observed that postoperative isoagglutinin titer elevations were often associated with fatal 
AMR, which was characterized by periportal edema, necrosis, and hemorrhage (2, 23). 
C4d deposition was commonly seen in portal stroma as well as the endothelium. In 
contrast, all ABO-I transplant recipients in this study underwent planned preoperative 
intravenous rituximab administration as well as plasmapheresis or blood exchange. As a 
result, most of the C4d-positive ABO-I cases had low Anti-A/B antibody titers at the time 
of biopsy and did not show histological evidence of critical graft injury. This is partly 
similar to the findings in ABO-I kidney allografts by Haas M et al. (26). The reason for 
this result may also be explained by considering the liver’s ability to absorb, eliminate, 
and neutralize antibodies. Mild alloantibody reactions may cause C4d deposition, but not 
significant allograft injury (8, 27). Another possibility is the presence of the 
accommodation phenomenon. In ABO-I renal allografts, graft resistance to the acute 
pathological effects of graft-specific antibodies even after the rebound of antibody 
concentrations has been referred to as accommodation (9). However, in our series, cases 
with postoperative elevations in anti-A/B antibody titers were associated with periportal 
changes that were compatible with acute antibody-mediated allograft injury accompanied 
by the focal or diffuse deposition of C4d. This suggests that postoperative titer monitoring 
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may be practical to predict acute AMR in patients with ABO-I transplantation and that 
the routine application of C4d immunostaining in ABO-I LT may not be necessary to 
detect acute AMR. 
Diffuse or strong C4d staining was uncommon in ABO-C cases, and none of the 
C4d-positive cases during the study period were associated with typical severe allograft 
rejection. We previously reported that lymphocyte cross-match positive transplantation 
without preventive conditioning against AMR could result in clinical AMR (1, 25). In that 
report, lymphocyte cross-match positive cases often showed diffuse C4d positivity and 
common histology were ACR, neutrophilic cholangitis/cholangiolitis, and 
hepatocanalicular cholestasis (1). After encountering some fatal clinical AMR cases, we 
tried to avoid lymphocyte cross-match positive transplantation. Therefore, patients in 
this study were all negative for lymphocytic cross-match tests before LT; C4d positivity 
was not associated with severe inflammation or cholestasis, which could suggest acute 
AMR after ABO-C LT. We suggest that avoiding cross-match-positive LT reduced critical 
AMR, but C4d positive cases may still be observed without severe graft damage. 
As in renal allografts, association of DSA and chronic rejection has been recognized in 
some studies in LT (5, 13). We have reported that anti-class II DSA was related to late 
graft fibrosis and C4d positivity (6). This study also proved that DSA against HLA-DR 
was associated with late-onset acute rejection, graft fibrosis and C4d deposition. While 
previous study focused on pediatric cases and excluded fibrosis with apparent causes 
such as steatohepatitis, this study included all biopsies of adult and pediatric patients 
whose fibrosis could be attributable to non-rejection episodes. It is of note that two adult 
patients who were treated with interferon for recurrent Hepatitis C were included among 
C4d-positive cases. Since chronic hepatitis C itself is associated with graft fibrosis, it 
seems difficult to determine if C4d has a role in graft fibrosis or not. Interferon therapy 
alone may be related to C4d positivity (14). In one of the two patients, however, 
Salah. C4d immunohistochemistry in liver allografts 15 
progression of fibrosis was observed even after sustained viral response and successful 
treatment of biliary stricture. Diffuse C4d positivity and persistent anti-class II (DR 
locus) DSA might be related to progressive fibrosis and bile duct loss. In addition, a 
pediatric case in which C4d positivity was found before this study was also associated 
with progressive fibrosis, which was a clue to prove HLA-DSA. These findings suggest 
that C4d can be a tool to detect possible DSA-related fibrosis; the causes of fibrosis can be 
multifactorial, especially among adults who may have recurrent original disease and 
positive DSA status at the same time. Since C4d positivity was rare and was not 
associated with graft loss or severe graft dysfunction, C4d immunohistochemistry seems 
to be useful only in limited situations for the evaluation of late allograft biopsies, such as 
immunosuppression weaning or unusual allograft fibrosis. However, C4d staining is 
inexpensive and can be easily evaluated using conventional biopsy, and would be more 
practical than applying HLA assays in all the cases after LT. The exact prognostic 
significance and contribution to optimization of immunosuppressants needs to be 
determined in further studies.  
Our study has several limitations for analysis of DSA. Pre-operative data of HLA assay 
other than lymphocyte crossmatch test were not available in most cases. Postoperative 
HLA assays were not performed in a fixed period of time after LT. Although negativity of 
preoperative lymphocyte crossmatch test suggests that most DSA found at late biopsies 
was associated with de novo DSA, definitive data is lacking in this study. Since presence 
of DSA did not correlated with the level of serum transaminases or total bilirubin, further 
study for alloantibody and autoantibody is also required in order to clarify the presence of 
chronic-antibody mediated rejection of the liver; assays for immunoglobulin subclass or 
complement fixation might be more important rather than simple quantification of those 
antibodies (28).  
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In conclusion, our study is the first to compare the prevalence of C4d positivity in liver 
allografts between ABO-C and ABO-I by applying C4d immunohistochemistry to routine 
anatomic pathology practice. In ABO-C LT, diffuse or strong endothelial C4d positivity is 
uncommon and may be associated with graft fibrosis and the presence of DSA against 
HLA DR. In ABO-I LT, C4d positivity is common with or without elevations in 
postoperative anti-A/B antibody titers, and is of little value to detect acute AMR. 
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Figure Legends 
Figure 1. A case of C4d-positive liver allograft biopsy after liver transplantation for 
hepatitis C cirrhosis. 1A, Biopsy taken 5 years after transplantation showing bridging 
portal fibrosis (Trichrome stain, x10 objective lens). HCV-RNA was negative in the 
serum; 1B, cytokeratin 7 immunostaining demonstrating focal bile duct loss and 
cytokeratin 7-positive hepatocytes (x 10); 1C, Mild lymphocytic portal infiltration without 
definite interface activity (H & E stain, x20); 1D, Diffuse C4d staining in the capillaries of 
the portal tract (x20). 
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Figure 2. A case of chronic allograft injury associated with persistent donor-specific HLA 
antibodies. 2A, Biopsy taken 185 days after transplantation revealed portal lymphocytic 
inflammation and perivenular hemorrhage, suggesting acute cellular rejection (H&E 
stain, ×4 objective lens); 2B, C4d was positive along the endothelium and stroma 
(postoperative day 185, x4, with inset highlighting the C4d-positive endothelium, ×20); 
2C, Follow-up biopsy showing portal fibrosis with focal lymphocytic portal infiltration 
(postoperative day 524, H&E stain, ×10); 2D, Faint C4d staining (postoperative day 524, 
×10); 2E, Last biopsy showing bridging perivenular and periportal fibrosis (postoperative 
day 968, Masson-Trichrome stain, ×4); 2F, C4d positivity returned (postoperative day 968, 
×40). 
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Figure 3. A case of acute antibody-mediated rejection after ABO-incompatible 
transplantation (postoperative day 9). 1A, Periportal edema and hemorrhage with mild 
neutrophilic infiltration (H&E stain, ×20 objective lens); 1B, C4d staining was seen along 






Table 1. The comparison of the ABO-compatible/identical patients and ABO-incompatible patients. 
  ABO-C (n = 114)  ABO-I (n = 29)    P value 
Age at LT  
(median, range)  4.7, 0.1–67.5  26.3, 0.1–66.7   - 
<18 years old  74%   38%    0.0007 
Female   49%   38%    0.2 
Indication for LT  BA (70%), HCV (12%) BA (31%), HCV (10%)  0.03, 1.0 
Biopsy >30 POD  91%   76%    0.05 
ACR   18%   42%    0.07 
C4d score 1-3*  35%   72%    0.0006 
C4d score 2-3*  4%   52%    <0.0001 
> 5000 MFI of DSA 32%   14%    0.1 
> 5000 MFI of  
DSA at DR locus  22%   9%    0.2 
Graft loss  3%   20%    0.002 
Abbreviations: ABO-C, ABO compatible/identical; ABO-I, ABO-incompatible; ACR, acute cellular rejection; DSA, 
donor-specific anti-HLA antibodies; HLA, human leukocyte antigen; LT, liver transplantation; POD, 
posttransplantation days 
*C4d score in the endothelium of portal areas: score 0, completely negative; score 1, focal and weak staining; score 2, 
diffuse or strong staining; score 3, diffuse and strong staining. 












ANA Histology of index 




Follow-up histology; DSA status and/or 
anti-A/B titer; C4d score (POD) 
C1 M 0.8 BA 14 DR8, 1329 - N/A Hepatocyte 
ballooning (1) 
Focal (2) Portal inflammation; NA; C4d socre 0 
(447) 




Focal (2) N/A 
C3 M 4.8 FHF 3245 DR8, 22701 - N/A ACR0 (2) Diffuse 
(3) 
Late ACR; DR DSA (+); C4d score 1 
(3634) 






Biliary stenosis; DR DSA (+); C4d score 3 
(2505) 
C5 F 58.8 HCV LC 1812 Negative - Negative  HepC (2) Focal (2) HepC; N/A; Score 0 (2162) 
I1 M 0.6 BA 8 Negative 1:32 N/A AMR (1) Focal (2) Mild ACR; DSA (-), anti-B, 1:2; C4d score 
2 (398) 
I2 F 0.6 BA 2289 NDSA (DR52, 
1495) 
<1:1 N/A ACR1 (1) Focal (2) Mild perivenular fibrosis; DSA (-); C4d 
score 0 (3000) 
I3 M 1.2 FHF 5 Negative 1:8 N/A ACR1 (1) Diffuse 
(2) 
Steatosis; DSA N/A, anti-B, 1:2; C4d 
score 0 (115) 
I4 M 6.9 PSC 1077 DR15, 5513; 
DR51, 21178; 
DQ6; 24806 
1:2 N/A ACR2 (1) Diffuse 
(2) 
N/A 
I5 F 17.8 BA 680 Negative <1:1 Positive 
33.6 
ACR3 (2) Diffuse 
(3) 
ACR0; DSA (-), anti-A, 1:4; C4d score 2 
(1160) 
I6 F 19.3 BA 174 Negative 1:2 N/A Cholangitis (2) Diffuse 
(3) 
Cholangitis; DSA (-), anti-A, 1:2; C4d 
score 3 (545) 
I7 M 26.1 IPH 68 N/A 1:4 N/A Congestion, 
hepatocyte 
inclusions (2) 
Focal (2) Liver abscess; DSA N/A, anti-A, <1:1; 
C4d score 0 (180) 
I8 F 33.3 EHE 9 Negative 1:256 N/A AMR (1) Diffuse 
(3) 
ACR0; N/A; C4d score 2 (68) 
I9 F 43.2 HBV LC 864 N/A <1:1 Negative ACR0 (1) Focal (2) N/A 
I10 F 45.7 BCS 34 Negative 1:2 N/A Cholangitis (2) Diffuse 
(3) 
Cholangitis; DSA N/A, anti-A <1:1; C4d 
score 2 (101) 
I11 M 46.0 PSC 2373 N/A <1:1 Positive 
87.6 
Cholangitis (1) Focal (2) N/A, (died of sepsis on POD 2404) 
I12 F 47.6 Alcoholic 
LC 
12 A31, 19571; 
DR9, 18175 
1:256 N/A AMR (1) Focal (2) ACR0; DSA (-), anti-A, 1:4; C4d score 0 
(675) 
I13 F 48.0 PBC 4903 Negative <1:1 Positive 
1:80 
Bile duct atrophy 
(1) 
Focal (2) N/A 
I14 F 51.6 HCV LC 6 Negative 1:2 N/A Cholangitis (1) Diffuse 
(2) 
Cholestatic hepatitis C; DSA N/A, 
anti-A, 1:2; C4d score 1 (452) 
I15 F 54.3 HCV LC 719 DR9; 1830; 
DR53; 2452; 
DQ9; 6156 
<1:1 N/A HepC (1) Focal (2) Chronic hepatitis C; DSA (-), anti-A, 1:4; 
C4d score 2 (1262) 
Abbreviations: ACR, Acute cellular rejection; (ACR0; indeterminate; ACR1, mild; ACR2, moderate; ACR3, severe); AMR, antibody-mediated rejection; ANA, 
anti-nuclear antibody; BA, biliary atresia; BCS, Budd-Chiari syndrome; DSA, donor-specific anti-hunan leukocyte antigen antibody; EHE, epithelioid 
hemangioendothelioma; F, fibrosis; FHF, fulminant hepatic failure; HCC, hepatocellular carcinoma; HCV, Hepatitis C virus; HBV, Hepatitis B virus; HepC, 
chronic hepatitis C; LC, liver cirrhosis; LT, Liver transplantation; MFI, mean fluorescence intensity; NDSA, non-donor-specific antibody; N/A, Not Available; P, 
positive; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; POD, postoperative day. 
*C1 to C5 are ABO-compatible/identical cases; I1 to I15 are ABO-incompatible transplantation cases. 
Table 3. Correlation of C4d positivity and clinicopathological parameters in ABO-compatible or ABO-identical liver transplantation 
      Early biopsy (<30 days posttransplantation)    Late biopsy (≥30 days posttransplantation) 
C4d status     C4d+ (n=1)  C4d- (n=9) P value  C4d+ (n=4) C4d- (n=100) P value 
Age at LT, years*     0.8      34 ± 26     -  31 ± 32    14 ± 20    0.11 
Age at biopsy, years*    0.8      34 ± 26    -  38 ± 28    24 ± 20    0.18 
POD, days*     14   13 ± 7  -  3034 ± 1427 2830± 1883 0.83 
AST (IU/L)*      164   83 ± 58  -  41 ± 24  39 ± 29  0.89 
ALT (IU/L)*      300   129 ± 132  -  39 ± 26  39 ± 50  1.00 
Total bilirubin (mg/dL)*     0.4   6 ± 4  -  0.6 ± 0.3  1.2± 1.9  0.53 
≥Stage 2 Fibrosis     0%   17%  1.00  100%  30%  0.01 
Acute cellular rejection    0%   58%  1.00  0%  14%  1.00 
>5000 MFI of DSA     0%   0%          1.00  75%  34%    0.12 
>5000 MFI of DSA at DR locus    0%   0%          1.00  75%  22%  0.04 
Graft loss      0%   11%          1.00  0%  2%  1.00 
Abbreviations: ALT, alanine Aminotransferase; AST, aspartate aminotransferase; DSA, donor-specific anti-human leukocyte antigen antibodies; LT, 
liver transplantation; MFI, mean fluorescence intensity. 
*Mean ± standard deviation. 
Table 4. Correlations of donor specific anti-HLA DR antibodies and 
clinicopathological parameters in late biopsies of ABO-compatible or identical 
patients 
   >5000 MFI MFI ≤5000 
                                           (n = 25)  (n = 79)   P value 
Age at LT, years* 7.9 ± 14.5 16.5 ± 22.0  0.07  
postoperative days* 3012 ± 1899 2782 ± 1859  0.74 
AST (IU/L)*  45  ± 37  45  ± 36   0.99 
ALT (IU/L)*  49  ± 63  52  ± 72   0.88 
TB (mg/dL)*  0.9  ± 0.5 1.7  ± 2.9  0.16 
≥Stage 2 Fibrosis 52%  27%   0.03 
ACR%   32%  8%   0.004 
C4d Score 2-3  12%  1%   0.04 
C4d Score 1-3  56%  27%   0.01 
Abbreviations: ACR, acute cellular rejection; ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; HLA, human leukocyte antigen; LT, liver 
transplantation; TB, Total Bilirubin.  
*Mean ± standard deviation. 
Table 5. Correlation of C4d positivity and clinicopathological parameters in ABO-incompatible liver transplantation 
   Early biopsy (<30 days posttransplantation)    Late biopsy (≥30 days posttransplantation) 
C4d status  C4d+ (n=5) C4d- (n=2) P value  C4d+ (n=10) C4d- (n=12) P value 
Age at LT, years*  27± 25   27 ± 33    0.9  31 ± 19    27 ± 27    0.7 
Age at biopsy, years* 26 ± 25  26 ± 33    0.9  34 ± 20     32 ± 32    0.8 
POD, days*  8 ± 3  18 ± 11            0.08  1318 ± 1508 1906 ± 1903 0.4 
AST (IU/L)*   82 ± 43  92 ± 23            0.8  68 ± 59  102 ± 170  0.8 
ALT (IU/L)*   129 ± 75  242 ± 193  0.3  74 ± 66  84 ± 136  0.7 
Total bilirubin (mg/dL)*  9 ± 8  10 ± 7  0.8  5 ± 8  2 ± 2  0.2 
≥ Stage 2 Fibrosis  0%  50%  0.3  60%  50%  0.8 
Acute cellular rejection 20%  100%  0.1  30%  25%  1.0 
Antibody-mediated rejection 60%  0%  0.4  0%  0%  - 
>5000 MFI of DSA  20% (1/5)  0% (0/2)  1.0  14% (1/7)  13% (1/8)  1.0 
>5000 MFI of DSA at DR locus 20% (1/5)  0% (0/2)   1.0  14% (1/7)  0% (0/8)  0.5 
>1:16 isoagglutinin titer 60%  0%  0.4  0%  0%  - 
Graft loss   2  0  1.0  3  1  0.3 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DSA, donor-specific anti-human leukocyte antigen antibodies; LT, 
liver transplantation; MFI, mean fluorescence intensity. 
*Mean ± standard deviation. 
